ALPHA TEKNOVA, INC. Revenue
ALPHA TEKNOVA, INC. (TKNO) reported Revenue of $12.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $12.19M, a 18.45% increase year-over-year.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $11.08M, a 13.09% increase year-over-year.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $9.98M, a 7.76% increase year-over-year.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $10.45M, a 9.17% increase year-over-year.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $40.52M, a 7.35% increase from fiscal 2024.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $37.74M, a 2.89% increase from fiscal 2023.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $36.68M, a 11.43% decline from fiscal 2022.
- ALPHA TEKNOVA, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $41.42M, a 12.27% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.19M 10-Q · filed 2026-08-06 | $23.26M 10-Q · filed 2026-08-06 | $33.25M derived: sum of 3 quarters · filed 2026-08-06 | $43.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.08M 10-Q · filed 2026-05-07 | $21.06M derived: sum of 2 quarters · filed 2026-05-07 | $31.52M derived: sum of 3 quarters · filed 2026-05-07 | $41.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $20.44M derived: sum of 2 quarters · filed 2026-03-02 | $30.73M derived: sum of 3 quarters · filed 2026-08-06 | $40.52M 10-K · filed 2026-03-02 |
| 2025-09-30 | $10.45M 10-Q · filed 2025-11-07 | $20.74M derived: sum of 2 quarters · filed 2026-08-06 | $30.54M 10-Q · filed 2025-11-07 | $39.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.29M 10-Q · filed 2026-08-06 | $20.08M 10-Q · filed 2026-08-06 | $29.35M derived: sum of 3 quarters · filed 2026-08-06 | $38.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.79M 10-Q · filed 2026-05-07 | $19.06M derived: sum of 2 quarters · filed 2026-05-07 | $28.64M derived: sum of 3 quarters · filed 2026-05-07 | $38.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $18.84M derived: sum of 2 quarters · filed 2026-03-02 | $28.45M derived: sum of 3 quarters · filed 2026-03-02 | $37.74M 10-K · filed 2026-03-02 |
| 2024-09-30 | $9.58M 10-Q · filed 2025-11-07 | $19.19M derived: sum of 2 quarters · filed 2025-11-07 | $28.48M 10-Q · filed 2025-11-07 | $36.35M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $9.61M 10-Q · filed 2025-08-08 | $18.90M 10-Q · filed 2025-08-08 | $26.77M derived: sum of 3 quarters · filed 2025-08-08 | $34.94M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $9.29M 10-Q · filed 2025-05-09 | $17.16M derived: sum of 2 quarters · filed 2025-05-09 | $25.33M derived: sum of 3 quarters · filed 2025-05-09 | $36.85M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $16.04M derived: sum of 2 quarters · filed 2025-03-07 | $27.56M derived: sum of 3 quarters · filed 2025-03-07 | $36.68M 10-K · filed 2025-03-07 |
| 2023-09-30 | $8.17M 10-Q · filed 2024-11-08 | $19.70M derived: sum of 2 quarters · filed 2024-11-08 | $28.82M 10-Q · filed 2024-11-08 | $36.71M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $11.53M 10-Q · filed 2024-08-13 | $20.65M 10-Q · filed 2024-08-13 | $28.54M derived: sum of 3 quarters · filed 2024-08-13 | $39.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $9.12M 10-Q · filed 2024-05-13 | $17.01M derived: sum of 2 quarters · filed 2024-05-13 | $27.70M derived: sum of 3 quarters · filed 2024-05-13 | $39.39M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $18.58M derived: sum of 2 quarters · filed 2024-03-27 | $30.27M derived: sum of 3 quarters · filed 2024-03-27 | $41.42M 10-K · filed 2024-03-27 |
| 2022-09-30 | $10.69M 10-Q · filed 2023-11-13 | $22.38M derived: sum of 2 quarters · filed 2023-11-13 | $33.53M 10-Q · filed 2023-11-13 | $43.64M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $11.69M 10-Q · filed 2023-08-11 | $22.84M 10-Q · filed 2023-08-11 | $32.95M derived: sum of 3 quarters · filed 2023-08-11 | $42.34M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $11.15M 10-Q · filed 2023-05-11 | $21.26M derived: sum of 2 quarters · filed 2023-05-11 | $30.65M derived: sum of 3 quarters · filed 2023-05-11 | $38.96M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $19.50M derived: sum of 2 quarters · filed 2023-03-30 | $27.82M derived: sum of 3 quarters · filed 2023-03-30 | $36.89M 10-K · filed 2023-03-30 |
| 2021-09-30 | $9.39M 10-Q · filed 2022-11-14 | $17.70M derived: sum of 2 quarters · filed 2022-11-14 | $26.78M 10-Q · filed 2022-11-14 | $36.94M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $8.31M 10-Q · filed 2022-08-11 | $17.39M 10-Q · filed 2022-08-11 | $27.55M derived: sum of 3 quarters · filed 2022-08-11 | $36.53M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $9.08M 10-Q · filed 2022-05-12 | $19.23M derived: sum of 2 quarters · filed 2022-05-12 | $28.22M derived: sum of 3 quarters · filed 2022-05-12 | $34.26M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $10.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $19.14M derived: sum of 2 quarters · filed 2022-03-18 | $25.18M derived: sum of 3 quarters · filed 2022-03-18 | $31.30M 10-K · filed 2022-03-18 |
| 2020-09-30 | $8.98M 10-Q · filed 2021-11-12 | $15.03M derived: sum of 2 quarters · filed 2021-11-12 | $21.14M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $6.04M 10-Q · filed 2021-08-13 | $12.16M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |